Safety, Tolerability, Effect of Vildagliptin and How the Body Changes the Blood Level of Vildagliptin in Healthy Chinese Volunteers

Novartis

Status and phase

Completed

Phase 1

Conditions

Healthy

Treatments

Drug: Vildagliptin (LAF237)

Study type

Interventional

Funder types

Industry

Identifiers

NCT00419887

CLAF237A2109

Details and patient eligibility

About

The purpose of this study is to assess the safety, tolerability, effect of vildagliptin and how the body changes the blood level of vildagliptin of single and multiple oral doses of vildagliptin in healthy Chinese volunteers.

Sex

All

Ages

18 to 45 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Chinese healthy volunteers age 18 to 45 years of age included
In good health as confirmed by past medical history, physical examination, electrocardiogram, laboratory tests and urinalysis on the screening and baseline evaluation
All subjects must have both parents of Chinese origin and citizenship and must have been born in China.
Body mass index (BMI) within the range of 19 to 24 kg/m2 and weigh at least 50 kg

Exclusion criteria

Smokers
Use of any prescription drugs within four (4) weeks prior dosing, or over-the-counter (OTC) medication (vitamins, herbal supplements, dietary supplements) within two (2) weeks prior to dosing. Paracetamol (or equivalent in China) is acceptable
Participation in any clinical investigation within 4 weeks prior to dosing or longer if required by local regulations, and for any other limitation of participation based on local regulations.
Donation or loss of 400 ml or more of blood within 8 weeks prior to first dosing, or longer if required by local regulation.
Significant illness within two weeks prior to dosing.
A past personal or close family medical history of clinically significant cardiac abnormalities
History of Acute or chronic bronchospastic disease (including asthma and chronic obstructive pulmonary disease) Clinically significant drug allergy or history of atopic allergy (asthma, urticaria, eczematous dermatitis) Known hypersensitivity or severe adverse event to darifenacin or similar drugs Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs or which may jeopardize participation in the study Immunodeficiency diseases, including a positive HIV (ELISA and Western blot) test result Positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result. Drug or alcohol abuse within the 12 months prior to dosing.

Other protocol-defined inclusion/exclusion criteria may apply